Revvity (NYSE:RVTY) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Revvity (NYSE:RVTY) announced its quarterly earnings results on Monday. The company reported $1.01 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.06, Zacks reports. Revvity had a return on equity of 7.68% and a net margin of 9.81%. Revvity updated its FY 2025 guidance to 4.900-5.000 EPS.

Revvity Stock Performance

Shares of NYSE RVTY opened at $94.30 on Monday. The firm’s 50-day moving average price is $104.87 and its 200-day moving average price is $112.98. Revvity has a 52-week low of $88.53 and a 52-week high of $129.50. The company has a market cap of $11.33 billion, a PE ratio of 42.67, a PEG ratio of 3.82 and a beta of 1.07. The company has a quick ratio of 3.03, a current ratio of 3.60 and a debt-to-equity ratio of 0.41.

Revvity Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 8th. Shareholders of record on Friday, July 18th will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.30%. The ex-dividend date is Friday, July 18th. Revvity’s dividend payout ratio (DPR) is 12.67%.

Insider Activity

In other Revvity news, insider Joel S. Goldberg sold 15,170 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $126.73, for a total transaction of $1,922,494.10. Following the completion of the sale, the insider now directly owns 33,400 shares in the company, valued at $4,232,782. The trade was a 31.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.68% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Raymond James reaffirmed an “outperform” rating and set a $145.00 target price (up previously from $140.00) on shares of Revvity in a research note on Monday, February 3rd. Wells Fargo & Company lowered their target price on Revvity from $130.00 to $102.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Barclays reduced their price target on Revvity from $140.00 to $110.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. Sanford C. Bernstein cut shares of Revvity from an “outperform” rating to a “market perform” rating and set a $130.00 target price on the stock. in a report on Friday, January 10th. Finally, KeyCorp increased their price target on shares of Revvity from $132.00 to $145.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Revvity presently has a consensus rating of “Moderate Buy” and a consensus target price of $130.50.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.